Latest Conference Articles

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

The Immune Effector Cell Encephalopathy score and keeping a close eye on patients’ symptoms are critical when monitoring for potential ICANS during lymphoma treatment.

A multidisciplinary approach to adverse effect management addresses many needs patients with gynecologic cancers may have while undergoing treatment.

Applying diversity, equity, and inclusion to cancer clinics can help oncology nurses and APPs make an impact on patient care and research.

An expert explained how oncology nurses and APPs should stay informed on the latest genetic mutations that targeted therapies focus in on for non-small cell lung cancer.

An expert discusses recent advancements in breast cancer treatment, focusing on the addition of CDK4/6 inhibitors for high-risk ER-positive, HER2-negative breast cancer.

Perioperative pembrolizumab plus chemotherapy improves overall survival in patients with resectable gastric cancer.

Durable complete responses were observed in patients with TP52-mutated mantle cell lymphoma treated with ibrutinib plus venetoclax.

The overall survival rate in patients with advanced biliary tract cancer treated with durvalumab plus chemotherapy was nearly double the rate of those treated with chemotherapy alone.

Nivolumab plus ipilimumab improved health-related quality of life and reduced symptom burden in patients with microsatellite instability–high/mismatch repair–deficient mCRC.

Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.

Final results of the ARMANI trial demonstrated that switch maintenance therapy with ramucirumab plus paclitaxel improved survival in advanced HER2-negative gastric or gastroesophageal junction cancer.

Assisted reproductive techniques may be safe for patients with BRCA-mutated breast cancer, according to an ESMO study.

Compared with epoetin alfa, treatment with luspatercept improved erythroid response rates and the duration of transfusion independence for lower-risk myelodysplastic syndromes.

Bispecific antibodies like teclistamab offer “more potent” treatment than monoclonal antibodies for patients with relapsed or refractory multiple myeloma.

The administration of CAR T-cell therapy in an outpatient setting was deemed feasible and safe for patients with relapsed/refractory non-Hodgkin lymphoma.

An oncology nurse practitioner highlights the benefits of attending conferences like the ASCO Annual Meeting.

Care teams should maintain frequent communication with patients with chronic myeloid leukemia to ensure best outcomes, even between appointments.

Treatment with acalabrutinib and bendamustine/rituximab in the frontline setting improved progression-free survival in older patients with MCL.

The health care team should provide an open forum for patients with chronic myeloid leukemia to discuss how adverse events from treatment affect daily function.

Patients who recently received a chronic myeloid leukemia diagnosis can benefit from initial discussions about treatment, side effects, and study results.

Glofitamab-gxbm plus gemcitabine and oxaliplatin significantly improved survival in relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

Resources are available to help patients through a chronic myeloid leukemia diagnosis and treatment.

Patients with newly diagnosed, high-risk acute promyelocytic leukemia treated with a combination strategy of ATO plus ATRA and idarubicin experienced improvements in event-free survival.

As most adverse effects of chronic myeloid leukemia treatment are manageable, patients with the disease may be able to continue their normal lifestyle while receiving therapy.

Most patients with lower-risk myelofibrosis, over a 4-year period, experienced disease progression, as demonstrated by the prospective MOST study.

New or worsening anemia may not reduce the clinical benefit derived from ruxolitinib treatment in patients with myelofibrosis.